Инфаркт миокарда у больных с фибрилляцией предсердий

Число пациентов с инфарктом миокарда (ИМ) и фибрилляцией предсердий (ФП) увеличивается с каждым годом. Эти больные представляют группу наиболее высокого риска и, соответственно, требуют особого внимания клиницистов. В статье рассмотрены механизмы взаимосвязи ФП и ИМ, особенности прогноза в зависимости от формы ФП и типа ИМ, проблема антитромботической терапии у больных данной категории. Отдельно выделяется группа ассоциированных с ФП эмбологенных ИМ, приводятся диагностические критерии и особенности лечения.

1. Сулимов В.А., Голицын С.П., Панченко Е.П., Попов С.В., Ревишвили А.Ш., Шубик Ю.В. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и ААСХ. Российский кардиологический журнал. 2013;18(4 S3):1-100

2. O’Neal WT, Sangal K, Zhang Z-M, Soliman EZ. Atrial Fibrillation and Incident Myocardial Infarction in the Elderly. Clinical Cardiology. 2014;37(12):750-5. https://doi.org/10.1002/clc.22339

3. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47. https://doi.org/10.1161/CIRCULATIONAHA.113.005119

4. Magnani JW, Rienstra M, Lin H, Sinner MF, Lubitz SA, McManus DD et al. Atrial Fibrillation: Current Knowledge and Future Directions in Epidemiology and Genomics. Circulation. 2011;124(18):1982-93. https://doi.org/10.1161/CIRCULATIONAHA.111.039677

5. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA et al. Atrial fibrillation and the risk of myocardial infarction. JAMA internal medicine. 2014;174(1):107-14. https://doi.org/10.1001/jamainternmed.2013.11912

6. Lopes RD, Pieper KS, Horton JR, Al-Khatib SM, Newby LK, Mehta RH et al. Shortand long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart (British Cardiac Society). 2008;94(7):867-73. https://doi.org/10.1136/hrt.2007.134486

7. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD et al. Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association. Circulation. 2011;123(8):933-44. https://doi.org/10.1161/CIR.0b013e31820a55f5

8. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. European Heart Journal. 2009;30(9):1038-45. https://doi.org/10.1093/eurheartj/ehn579

9. Bengtson LGS, Chen LY, Chamberlain AM, Michos ED, Whitsel EA, Lutsey PL et al. Temporal Trends in the Occurrence and Outcomes of Atrial Fibrillation in Patients With Acute Myocardial Infarction (from the Atherosclerosis Risk in Communities Surveillance Study). The American Journal of Cardiology. 2014;114(5):692-7. https://doi.org/10.1016/j.amjcard.2014.05.059

10. Vermond RA, Van Gelder IC, Crijns HJ, Rienstra M. Does Myocardial Infarction Beget Atrial Fibrillation and Atrial Fibrillation Beget Myocardial Infarction? Circulation. 2015;131(21):1824-6. https://doi.org/10.1161/CIRCULATIONAHA.115.016595

11. Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E et al. Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. Journal of the American College of Cardiology. 2005;45(9):1397-405. https://doi.org/10.1016/j.jacc.2005.01.041

12. Радха Б., Сайганов С.А., Громыко Т.Ю. Фибрилляция предсердий у больных с инфарктом миокарда нижней локализации. Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2015;7(1):46-52

13. Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. Journal of the American College of Cardiology. 2012;60(22):2263- 70. https://doi.org/10.1016/j.jacc.2012.04.063

14. Kolodgie FD, Virmani R, Finn AV, Romero ME. Embolic Myocardial Infarction as a Consequence of Atrial Fibrillation: A Prevailing Disease of the Future. Circulation. 2015;132(4):223-6. https://doi.org/10.1161/CIRCULATIONAHA.115.017534

15. Soliman EZ, Lopez F, O’Neal WT, Chen LY, Bengtson L, Zhang Z-M et al. Atrial Fibrillation and Risk of ST-Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015;131(21):1843-50. https://doi.org/10.1161/CIRCULATIONAHA.114.014145

16. Марцевич С.Ю., Кутишенко Н.П., Гинзбург М.Л., Дроздова Л.Ю., Деев А.Д., Смирнов В.П. Влияние фибрилляции предсердий на ближайший и отдаленный прогноз жизни при остром инфаркте миокарда. Данные исследования ЛИС-1 (люберецкое исследование смертности больных, перенесших острый инфаркт миокарда). Рациональная фармакотерапия в кардиологии. 2014;10(2):170-3. https://doi.org/10.20996/1819-6446-2014-10-2-170-173

17. Kundu A. Recent Trends In Oral Anticoagulant Use And Post-Discharge Complications Among Atrial Fibrillation Patients With Acute Myocardial Infarction. Journal of Atrial Fibrillation. 2018;10(5):1749. https://doi.org/10.4022/jafib.1749

18. Reinstadler SJ, Stiermaier T, Eitel C, Fuernau G, Saad M, Pöss J et al. Impact of Atrial Fibrillation During ST-Segment-Elevation Myocardial Infarction on Infarct Characteristics and Prognosis. Circulation: Cardiovascular Imaging. 2018;11(2):e006955. https://doi.org/10.1161/CIRCIMAGING.117.006955

19. Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ, Weston SA et al. Atrial Fibrillation and Death After Myocardial Infarction: A Community Study. Circulation. 2011;123(19):2094-100. https://doi.org/10.1161/CIRCULATIONAHA.110.990192

20. Consuegra-Sánchez L, Melgarejo-Moreno A, Galcerá-Tomás J, Alonso-Fernández N, Díaz-Pastor Á, Escudero-García G et al. Shortand Long-term Prognosis of Previous and New-onset Atrial Fibrillation in ST-segment Elevation Acute Myocardial Infarction. Revista Española de Cardiología (English Edition). 2015;68(1):31-8. https://doi.org/10.1016/j.rec.2014.03.017

21. Lehto M, Snapinn S, Dickstein K, Swedberg K, Nieminen MS, OPTIMAAL investigators. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. European Heart Journal. 2005;26(4):350-6. https://doi.org/10.1093/eurheartj/ehi064

22. Maagh P, Butz T, Wickenbrock I, Prull MW, Plehn G, Trappe H-J et al. New-onset versus chronic atrial fibrillation in acute myocardial infarction: differences in shortand long-term follow-up. Clinical Research in Cardiology. 2011;100(2):167-75. https://doi.org/10.1007/s00392-010-0227-6

23. Batra G, Svennblad B, Held C, Jernberg T, Johanson P, Wallentin L et al. All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart. 2016;102(12):926- 33. https://doi.org/10.1136/heartjnl-2015-308678

24. Batra G, Friberg L, Erlinge D, James S, Jernberg T, Svennblad B et al. Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention. European Heart Journal Cardiovascular Pharmacotherapy. 2018;4(1):36-45. https://doi.org/10.1093/ehjcvp/pvx033

25. Saaby L, Poulsen TS, Hosbond S, Larsen TB, Pyndt Diederichsen AC, Hallas J et al. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. The American Journal of Medicine. 2013;126(9):789-97. https://doi.org/10.1016/j.amjmed.2013.02.029

26. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA et al. Fourth universal definition of myocardial infarction (2018). European Heart Journal. 2019;40(3):237-69. https://doi.org/10.1093/eurheartj/ehy462

27. Prizel KR, Hutchins GM, Bulkley BH. Coronary artery embolism and myocardial infarction. Annals of Internal Medicine. 1978;88(2):155- 61. https://doi.org/10.7326/0003-4819-88-2-155

28. Фролов А.А., Шарабрин Е.Г., Савенков А.Г., Ботова С.Н. Эмбологенный инфаркт миокарда: взгляд эндоваскулярного хирурга. Кардиология: новости, мнения, обучение. 2016;2(9):54-8

29. Shibata T, Kawakami S, Noguchi T, Tanaka T, Asaumi Y, Kanaya T et al. Prevalence, Clinical Features, and Prognosis of Acute Myocardial Infarction Attributable to Coronary Artery Embolism. Circulation. 2015;132(4):241-50. https://doi.org/10.1161/CIRCULATIONAHA.114.015134

30. Popovic B, Agrinier N, Bouchahda N, Pinelli S, Maigrat CH, Metzdorf PA et al. Coronary Embolism Among ST-Segment-Elevation Myocardial Infarction Patients: Mechanisms and Management. Circulation: Cardiovascular Interventions. 2018;11(1):e005587. https://doi.org/10.1161/CIRCINTERVENTIONS.117.005587

31. Шульман В.А., Шестерня П.А., Головенкин С.Е., Радионов В.В. Фибрилляция предсердий у больных инфарктом миокарда: предикторы возникновения, влияние на ближайший и отдаленный прогноз. Вестник аритмологии. 2005;39:5-9

32. Goto S, Bhatt DL, Röther J, Alberts M, Hill MD, Ikeda Y et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. American Heart Journal. 2008;156(5):855-863.e2. https://doi.org/10.1016/j.ahj.2008.06.029

33. Lau DH, Huynh LT, Chew DP, Astley CM, Soman A, Sanders P. Prognostic impact of types of atrial fibrillation in acute coronary syndromes. The American Journal of Cardiology. 2009;104(10):1317-23. https://doi.org/10.1016/j.amjcard.2009.06.055

34. Lip GYH, Lane DA. Does Warfarin for Stroke Thromboprophylaxis Protect Against MI in Atrial Fibrillation Patients? The American Journal of Medicine. 2010;123(9):785-9. https://doi.org/10.1016/j.amjmed.2010.01.031

35. Беленков Ю.Н., Шакарьянц Г.А., Хабарова Н.В. Тактика подбора антикоагулянтной терапии у пациентов с фибрилляцией предсердий и ишемической болезнью сердца. Кардиология. 2018;58(3):4352. https://doi.org/10.18087/cardio.2018.3.10098

36. Mak K-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2(5):e001592. https://doi.org/10.1136/bmjopen-2012-001592

37. Tornyos A, Kehl D, D’Ascenzo F, Komócsi A. Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment. Progress in Cardiovascular Diseases. 2016;58(5):483-94. https://doi.org/10.1016/j.pcad.2015.12.001

38. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883-91. https://doi.org/10.1056/NEJMoa1009638

39. Zeymer U, Annemans L, Danchin N, Pocock S, Newsome S, Van de Werf F et al. Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry. European Heart Journal: Acute Cardiovascular Care. 2019;8(2):121-9. https://doi.org/10.1177/2048872618769057

40. Biasco L, Radovanovic D, Moccetti M, Rickli H, Roffi M, Eberli F et al. New-onset or Pre-existing Atrial Fibrillation in Acute Coronary Syndromes: Two Distinct Phenomena With a Similar Prognosis. Revista Española de Cardiología (English Edition). 2019;72(5):383-91. https://doi.org/10.1016/j.rec.2018.03.002

41. Stenestrand U. Anticoagulation Therapy in Atrial Fibrillation in Combination With Acute Myocardial Infarction Influences Long-Term Outcome: A Prospective Cohort Study From the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation. 2005;112(21):3225-31. https://doi.org/10.1161/CIRCULATIONAHA.105.552984

42. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019;40(2):87-165. https://doi.org/10.1093/eurheartj/ehy394

43. Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen A-M, Mikkelsen A et al. Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention. Journal of the American College of Cardiology. 2013;62(11):981-9. https://doi.org/10.1016/j.jacc.2013.05.029

44. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. Рекомендации ESC по лечению пациентов с фибрилляцией предсердий, разработанные совместно с EACTS. Российский кардиологический журнал. 2017;22(7):7-86]. https://doi.org/10.15829/1560-4071-2017-7-7-86

45. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. The New England Journal of Medicine. 2016;375(25):2423-34. https://doi.org/10.1056/NEJMoa1611594

46. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. The New England Journal of Medicine. 2017;377(16):1513- 24. https://doi.org/10.1056/NEJMoa1708454

47. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. New England Journal of Medicine. 2019;380(16):1509-24. https://doi.org/10.1056/NEJMoa1817083

48. Matsumura-Nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H et al. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation: OAC-ALONE Study. Circulation. 2019;139(5):604-16. https://doi.org/10.1161/CIRCULATIONAHA.118.036768

49. Jiao Z-Y, Zhang D-P, Xia K, Wang L-F, Yang X-C. Clinical analysis of acute myocardial infarction caused by coronary embolism. Journal of Thoracic Disease. 2017;9(9):2898-903. https://doi.org/10.21037/jtd.2017.07.92